The present work examined the potential of using ARV-825 and ABBV-744 to boost the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in both of those p53 wild-form (WT) breast tumor cells and in cells missing useful p53 both alone or in combination with tamoxifen, though https://carlf888erc2.wikigop.com/user